IMMUNITYBIO, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
IMMUNITYBIO, INC. (IBRX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$116.56 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2023-05-11
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2023-03-31 was -$116.56M.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2022-12-31 was -$107.84M.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2022-09-30 was -$111.02M.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2022-06-30 was -$94.33M.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$416.39M.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2021 was -$346.91M.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2020 was -$221.64M.
- IMMUNITYBIO, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2019 was -$157.65M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2023-03-31 | -$116.56M 10-Q · filed 2023-05-11 | -$224.40M derived: sum of 2 quarters · filed 2023-05-11 | -$335.42M derived: sum of 3 quarters · filed 2023-05-11 | -$429.75M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | -$107.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$218.86M derived: sum of 2 quarters · filed 2023-03-01 | -$313.19M derived: sum of 3 quarters · filed 2023-03-01 | -$416.39M 10-K · filed 2023-03-01 |
| 2022-09-30 | -$111.02M 10-Q · filed 2022-11-09 | -$205.35M derived: sum of 2 quarters · filed 2022-11-09 | -$308.55M 10-Q · filed 2022-11-09 | -$399.85M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-06-30 | -$94.33M 10-Q · filed 2022-08-08 | -$197.53M 10-Q · filed 2022-08-08 | -$288.84M derived: sum of 3 quarters · filed 2023-05-11 | -$376.45M derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-03-31 | -$103.20M 10-Q · filed 2023-05-11 | -$194.50M derived: sum of 2 quarters · filed 2023-05-11 | -$282.12M derived: sum of 3 quarters · filed 2023-05-11 | -$370.33M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$91.31M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$178.92M derived: sum of 2 quarters · filed 2023-03-01 | -$267.13M derived: sum of 3 quarters · filed 2023-03-01 | -$346.91M 10-K · filed 2023-03-01 |
| 2021-09-30 | -$87.61M 10-Q · filed 2022-11-09 | -$175.83M derived: sum of 2 quarters · filed 2022-11-09 | -$255.60M 10-Q · filed 2022-11-09 | -$323.13M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$88.21M 10-Q · filed 2022-08-08 | -$167.99M 10-Q · filed 2022-08-08 | -$235.51M derived: sum of 3 quarters · filed 2023-03-01 | -$301.16M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$79.77M 10-Q · filed 2022-05-10 | -$147.30M derived: sum of 2 quarters · filed 2023-03-01 | -$212.95M derived: sum of 3 quarters · filed 2023-03-01 | -$264.43M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | -$67.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$133.18M derived: sum of 2 quarters · filed 2023-03-01 | -$184.65M derived: sum of 3 quarters · filed 2023-03-01 | -$221.64M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$65.65M 10-Q · filed 2021-11-12 | -$117.12M derived: sum of 2 quarters · filed 2021-11-12 | -$154.11M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$51.47M 10-Q · filed 2021-08-12 | -$88.47M 10-Q · filed 2021-08-12 | ||
| 2019-12-31 | -$157.65M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |